Wall Street is paying attention to FBR’s George Zavoico’s surge in enthusiasm on Novavax’s prospects.
Cantor’s William Tanner is not thrilled as he joins a disgruntled Street saying goodbye to what could have been a meaningful catalyst for NVAX shares before the end of 2017: NanoFlu vaccine top-line data.
Novavax, Inc. (NASDAQ:NVAX) announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal …
Novavax, Inc. (NASDAQ:NVAX) announced that Barclay A.
